MedTrace Logo

Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .

NCT02788006 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2024-02-23

Study results available
· View outcomes & findings →

Summary

Multicenter prospective phase II study evaluating regorafenib in older patients with metastatic colorectal cancer

Conditions

  • Colorectal Adenocarcinoma

Interventions

DRUG

Regorafenib 160 mg

Sponsors & Collaborators

  • Federation Francophone de Cancerologie Digestive

    lead OTHER

Principal Investigators

  • Thomas APARICIO, Pr · Hôpital Avicenne BOBIGNY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-08-31
Completion
2017-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02788006 on ClinicalTrials.gov